Contineum Therapeutics, Inc.

CTNM

$17.57

+1.91%

N/A+$0.33

Healthcare

Biotechnology

NASDAQ

Active Trading

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications ...

Key Metrics of CTNM

Snapshot

Latest / TTM · 6 periods

Market Cap

$661.00M

ROCE

-27.2%

EV / EBITDA

-9.89x

-1.7% YoY

FCF Yield

-8.1%

+9.5% YoY

Cash Conversion Cycle

0.0d

Current Ratio

37.17

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$387.01M	$387.01M	$387.01M	$378.77M	$316.62M	$661.00M
Enterprise ValueCompany value including debt and cash adjustments.	$387.29M	$387.29M	$564.68M	$363.09M	$249.27M	$652.87M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	11.29x	0.00x	0.00x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-13.67x	-16.46x	23.95x	-8.64x	-3.68x	-9.89x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	-0.01	-0.01	7.54	0.37	0.99	0.12

Market-based metrics start from the IPO on 4/4/2024; earlier periods had no public share price.

Returns + ROCE gauge

ROCE latest

-27.2%

Prev year -25.5%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-47.1%	-61.8%	-33.4%	-21.3%	-23.0%	-24.7%
ROAProfit generated from total assets.	-41.1%	-47.9%	17.4%	-19.9%	-21.7%	-23.0%
ROICReturn generated on invested operating capital.	-43.0%	-55.6%	18.5%	-20.8%	-25.5%	-27.3%
ROCEOperating return on long-term capital used.	-42.9%	-52.7%	-12.9%	-25.1%	-25.5%	-27.2%
Earnings YieldEarnings as a percentage of market value.	-7.5%	-6.3%	5.9%	-11.2%	-18.9%	-8.7%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-26.10M	$-19.85M	$19.14M	$-33.36M	$-55.54M	$-53.46M
FCFECash flow available to equity holders after debt flows.	$-26.43M	$-21.49M	$15.19M	$-33.36M	$-55.54M	$-53.46M
FCF YieldFree cash flow divided by market capitalization.	-6.8%	-5.2%	4.9%	-8.8%	-17.5%	-8.1%
Income QualityHow well accounting earnings are backed by cash flow.	0.91	0.83	0.85	0.78	0.92	0.92
Capex / OCFShare of operating cash flow spent on capital expenditures.	-0.6%	-0.6%	2.1%	-1.6%	-0.4%	-0.9%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	2562.1d	0.0d	0.0d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	0.0d	0.0d	0.0d	-2562.1d	0.0d	0.0d

Snapshot

Latest / TTM: —

Market Cap

$661.00M

ROE

-24.7%

FCF Yield

-8.1%

Current Ratio

37.17

Supply Chain of CTNM

Upstream / Downstream / Proxies

Upstream

Third-Party CMO (API Manufacturing)Third-Party CMO (Drug Product Manufacturing)Third-Party CRO (Clinical Trial Management)Preclinical CRO PartnersSpecialty Chemical / Raw Material SuppliersSpecialty Chemical Distributors (e.g., Sigma-Aldrich/Merck, Thermo Fisher)NYSE:MRK Laboratory Equipment SuppliersNYSE:TMO

Downstream

Johnson & Johnson (Janssen Pharmaceutica NV)NYSE:JNJNo commercial customers (pre-revenue, clinical-stage)No commercial distributors (pre-revenue, clinical-stage)

Proxies

Johnson & JohnsonNYSE:JNJVersant VenturesUnconfirmedReata Pharmaceuticals / BiogenUnconfirmedPliant TherapeuticsNASDAQ:PLRX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer